Combination radiation and immunotherapy for large tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of low-dose radiation, focused high-dose radiation, and an immunotherapy drug (tislelizumab) for people with large, advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that has spread (stage IV) and is larger than 5 cm in size.
- You must have tried standard treatments that no longer work, or you cannot take them.
- You need to be willing to have a repeat biopsy of your tumor.
- You must be at least 18 years old.
- You need to be in generally good health (able to care for yourself and up and about more than half of waking hours).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This trial tests a new combination of radiation therapy and two immunotherapy drugs (Iparomlimab and Tuvonralimab) for people whose solid tumors have returned or spread and are too large for standard surgery. The goal is to shrink the tumor and control the cancer.
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.